Aptus Capital Advisors LLC Boosts Position in Johnson & Johnson (NYSE:JNJ)

Aptus Capital Advisors LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 7.2% in the third quarter, Holdings Channel reports. The institutional investor owned 77,500 shares of the company’s stock after buying an additional 5,177 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Johnson & Johnson were worth $12,661,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. RKL Wealth Management LLC boosted its position in shares of Johnson & Johnson by 2.1% during the 2nd quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock valued at $8,562,000 after acquiring an additional 1,010 shares during the last quarter. Geller Advisors LLC boosted its position in shares of Johnson & Johnson by 7.5% during the 2nd quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock valued at $1,644,000 after acquiring an additional 648 shares during the last quarter. Simon Quick Advisors LLC boosted its position in shares of Johnson & Johnson by 296.9% during the 2nd quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock valued at $1,495,000 after acquiring an additional 6,537 shares during the last quarter. Lokken Investment Group LLC boosted its position in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock valued at $2,302,000 after acquiring an additional 201 shares during the last quarter. Finally, Keebeck Alpha LP boosted its position in shares of Johnson & Johnson by 13.4% during the 2nd quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock valued at $788,000 after acquiring an additional 525 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on JNJ shares. StockNews.com started coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. SVB Leerink dropped their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Atlantic Securities dropped their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Raymond James dropped their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Finally, Bank of America dropped their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Insider Activity

In other news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Ashley Mcevoy sold 73,323 shares of the company’s stock in a transaction on Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total value of $12,865,986.81. Following the sale, the executive vice president now directly owns 41,813 shares of the company’s stock, valued at $7,336,927.11. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The disclosure for this sale can be found here. Over the last three months, insiders have sold 233,611 shares of company stock valued at $40,960,735. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $168.31 on Wednesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock has a 50 day moving average price of $175.98 and a two-hundred day moving average price of $171.06. The company has a market capitalization of $440.04 billion, a P/E ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.23 by $0.12. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. During the same quarter in the previous year, the company posted $2.13 earnings per share. The business’s revenue was down 4.4% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.